1374.6.
(a) An individual or group health care service plan contract that is issued, amended, or renewed on or after January 1, 2025, shall include comprehensive coverage for the treatment of obesity, including coverage for intensive behavioral therapy, bariatric surgery, and FDA-approved antiobesity medication.(b) Coverage criteria for FDA-approved antiobesity medications shall not be more restrictive than the FDA-approved indications for those treatments.
(c) Coverage under this section shall not be different or separate from coverage for any other illness, condition, or disorder for purposes of determining deductibles, copayment and coinsurance factors, and benefit year maximums for deductibles and copayment and coinsurance factors.
(d) This section does not prohibit a plan from applying utilization management to determine the medical necessity for treatment of obesity under this section if appropriateness and medical necessity determinations are made in the same manner as those determinations are made for the treatment of any other illness, condition, or disorder covered by a contract.
(e) For purposes of this section, “FDA-approved antiobesity medication” means any medication approved by the United States Food and Drug Administration with an indication for chronic weight management in patients with obesity.
(f) This section does not apply to a specialized health care service plan contract that covers only dental or vision benefits or a Medicare supplement contract.